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The stabilizing effect of an oligomeric proanthocyanidin on red
blood cell membrane structure of poorly controlled Type II
diabetes
J Visser1, PJ van Staden2, P Soma1, AV Buys3 and E Pretorius4
Type II diabetes (T2D) is a pandemic characterized by pathological circulating inﬂammatory markers, high-glucose levels and
oxidative stress. The hematological system is especially vulnerable to these aberrant circulating molecules, and erythrocytes (RBCs)
show aberrant rheology properties, owing to the direct contact with these molecules. Pathological levels of circulating
inﬂammatory markers in T2D therefore have a direct effect on the molecular and cellular structure of RBCs. Previous research has
suggested that antioxidants may reduce oxidative stress that results from the pathological inﬂammatory markers. Particularly,
polyphenol antioxidants like oligomeric proanthocyanidins (OPCs) may act as a hydroxyl mopping agent, and may have a positive
effect on the deformability and membrane protein structure of RBCs from T2D. In this paper, we look at the effect of one such
agent, Pinus massoniana bark extract (standardized to 95% oligomeric proanthicyanidins), on the RBC membrane structures and
RBC shape changes of T2D, after laboratory exposure at physiological levels. Our methods of choice were atomic force microscopy
and scanning electron microscopy to study RBC elasticity and ultrastructure. Results showed that in our hands, this OPC could
change both the eryptotic nature of the RBCs, as viewed with scanning electron microscopy, as well as the elasticity. We found a
signiﬁcant difference in variation between the elasticity measurement values between the RBCs before and after OPC exposure
(P-value o0.0001). In conclusion, the data from both these techniques therefore suggest that OPC usage might contribute to the
improvement of RBC functioning.
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INTRODUCTION
Type II diabetes (T2D) is commonly associated with comorbidities
including dyslipidaemia1–4 and hypertension.4,5 The main cause of
morbidity and mortality in individuals with T2D is cardiovascular
disease (CVD), with up to 80% of diabetes subjects dying as a
result of cardiovascular complications.1,3,6 The risk of athero-
thrombotic events is also comparable to individuals without
diabetes but with a history of ischemic heart disease.1 Further-
more, the prognosis in these individuals following an event
remains poor, despite major advances in treatment1 such as
antiplatelet therapies, and the control of the modiﬁable risk
factors like hypertension, obesity, smoking and dyslipidaemia.7
Changed inﬂammatory marker levels, oxidative stress and
chronic (systemic) inﬂammation, all lead to a pathophysiological
coagulation system that is characterized by hypercoagulability.
Systemic inﬂammation has a fundamental role in many chronic
conditions, including T2D and CVD.8–12 CVD and vascular
dysfunction are fundamental parts of the etiology of T2D and
this condition is also known to have a changed coagulation
system. Therefore, all these factors serve as early indicators of
vascular dysfunction. Thus, there are important links between
oxidative stress, a changed inﬂammatory marker proﬁle and
inﬂammation, the progression of T2D and ultimately, vascular
dysfunction.4
Dysregulated inﬂammatory markers, either upregulated or
downregulated, are associated with diabetes.4 These inﬂammatory
markers are mainly C-reactive protein,13,14 coagulation factors,14–18
nitric oxide,19–23 tumor necrosis factor-α, nuclear factor kappa-B,
cyclooxygenase-2,24–28 prostaglandin-2,29,30 Interleukin-616,17,29,31,32
and thromboxane A2.33,34
A fundamental part of a pathological coagulation system and a
systemic hypercoagulability, is an altered erythrocyte (RBC)
function. All of the above-mentioned circulating inﬂammatory
markers have a noticeable effect on RBC functioning, speciﬁcally
on their rheology properties. Hypercoagulability affects ﬁbrin
(ogen) and this in turn also directly impacts on RBC rheology. It is
also thought that abnormalities of high blood glucose as is the
case in insulin resistance, and relative insulin deﬁciency, may have
a negative effect on the structure and function of RBCs at
molecular scale.4
Pathological levels of circulating inﬂammatory markers, high-
glucose levels and the associated oxidative stress in T2D therefore
have a direct effect on the molecular and cellular structure of
RBCs. Their membranes consist of the typical lipid bilayer, the
actin–spectrin cortex and the integral and peripheral membrane
proteins,35,36 of which ~ 20 are major proteins and at least
850 minor ones.35 In particular, ﬂippases, ﬂoppases and scram-
blases (integral proteins) facilitate the transmembrane passage, as
well as the structural arrangement of lipids RBC membranes.
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Structural alterations, owing to the systemic inﬂammatory proﬁle
in T2D, are known to affect the RBC membrane lipids, as well as
band 3 and spectrin, which in turn cause RBC structural shape
changes.36,37 For an in-depth review of the RBC membrane
structure, see reference Pretorius et al.38
AS oxidative stress is known to have a role in the progression of
T2D4,23,39,40 and biophysical shape changes of RBCs,36,41 the
question that now arose is whether there is a polyphenol
antioxidant that may act as a hydroxyl mopping agent, and may
have a positive effect on the deformability and membrane protein
structure of RBCs from T2D that can be added to the diet. A group
of (polyphenolic) antioxidants found in pine bark extract and
grape seed extract that may have an effect, is the oligomeric
proanthocyanidins (OPCs). Various preliminary clinical trials have
been conducted investigating the effect of OPCs in several
indications and clinical contexts including asthma, CVD and
diabetes.42–47
It has been shown that OPCs increase erythrocyte membrane
ﬂuidity in vitro, potentially due to inducing modiﬁcation of the
lipid bilayer and lipid–protein interactions as shown by Sivonova
and co-workers in 2004.42 In an in vitro study, OPCs (0.07 mg ml− 1)
resulted in 50% inhibition of the formation of erythrocytes with
elevated density (increased adherence to neutrophils, platelets
and vascular endothelial cells) from patients with sickle cell
anemia.48 OPCs have also been shown to have anti-inﬂammatory
effects. It has been demonstrated to inhibited cyclooxygenase-1
and -2 activity49 and reducing the production of interleukin-1beta
and its associated mRNA in vitro, as well as the expression of IL-2.50
Activation of two major transcription factors heavily involved in
interleukin-1beta gene expression, nuclear factor kappa-B and
activator protein-1, have also been shown to be reduced.
In the current study, we therefore investigated the effect of the
addition of physiological levels of OPCs (Pinus massoniana bark
extract standardized to 95% oligomeric proanthicyanidins), on the
RBC membrane structures and RBC shape changes of T2D. Shape
changes or patho-morphological changes are closely associated
with RBC properties including area deformability, such as
membrane elasticity changes due to membrane biochemical
changes as discussed previously, and directly translate as
biophysical indicators. In this study, atomic force microscopy
(AFM) was used to evaluate membrane elasticity, whereas
scanning electron microscopy (SEM) was used to evaluate physical
changes. Although a randomized control trial is obviously the
most useful way to establish the effect of any molecule (dietary or
otherwise) it is of great importance to ﬁrst establish if the
molecule has any effect in vitro.
MATERIALS AND METHODS
This study was approved by the Ethical Committee of the University of
Pretoria (South Africa). A written form of informed consent was obtained
from all healthy donors (available on request). The methods were carried out
in accordance with the approved guidelines. Blood was collected and
methods were carried out in accordance with the relevant guidelines of the
ethics committee (ethics number: 506/2014 and 298/2016: E Pretorius and
J Bester: principal investigators for use of control blood; ethics number:
151/2006 for T2D study). We adhered strictly to the Declaration of Helsinki.
Samples used
We recruited 20 healthy individuals with no systemic inﬂammation, and
who did not use any chronic medication, as our control group. T2D
individuals were voluntarily recruited, from the Diabetic Clinic at the Steve
Biko academic hospital, Pretoria, South Africa. Demographic data including
age, gender, glucose level at time of sample collection, hemoglobin A1c
(HbA1c) measures and medication used for typical comorbidities of T2D
were recorded. Inclusion criteria consisted of both male and female
participants, aged between 19 and 70, with a diagnosis of T2D for
43 months prior to screening and without any signs of infection. Smoking
was an exclusion criteria and our samples consisted of individuals (control
and T2D) who did not smoke. Diabetic individuals were diagnosed
according to the Society for Endocrinology, Metabolism and Diabetes of
South Africa (SEMSDA) guidelines. These guidelines follow the American
Diabetes Association (ADA) criteria to deﬁne T2D.
An important consideration might be that these OPCs should not
interact negatively with the currently used medications that typical poorly
controlled diabetes patients may be taking. Therefore, a literature search
was also done to investigate possible interactions of OPCs with medication
typically prescribed for comorbidities associated with T2D.
Dosage of OPCs
The standard daily dosage of pine bark extract standardized to 95% OPCs
for people with diabetes is 50–200 mg per day.43,47,51,52 The extract that
was used is a 4:1 concentrated extract. Therefore, in order to reach a daily
dosage of 200 mg, 50 mg was used. Based on an average individual of
70 kg, the ﬁnal concentration in the blood is expected to be 9 μg ml− 1.
Therefore, the exposure concentration for both the AFM and SEM
experiments was 9 μg ml− 1.
Sample preparation for AFM
Whole blood samples were centrifuged at 145 g for 30 s. The supernatant
consisting of plasma, platelets and leukocytes, was discarded. The
remaining RBCs were prepared for AFM by ﬁxing in 4% formaldehyde
made up in phosphate-buffered saline for 30 min, at room temperature
(22 °C) followed by dehydration. RBCs were suspended in undiluted
(161.39 g mol− 1) hexamethyldisilazane onto a glass cover slip by placing a
drop and spreading the ﬂuid by tilting the cover slip sideways, ensuring an
even distribution of cells. The cover slips were then dried and stored until
AFM analysis.
AFM imaging and measurement
The cells were characterized with a commercial AFM system (Dimension
Icon with ScanAsyst, Bruker, Santa Barbara, CA, USA) using the PeakForce
QNM (Quantitative Nanomechanical Property Mapping) imaging mode.
This method is similar to the standard tapping mode of scanning probe
microscopy, where the probe and the sample are brought together
intermittently. See Bester and co-workers 2013,53 for a comprehensive
discussion of the AFM methods used in this paper. This mode operates by
controlling the maximum force applied by the probe to the sample54 and
allows that at every pixel a rapid force–distance curve is generated. The
cantilever’s deﬂection sensitivity and spring constant is calibrated before
measurements, therefore the curve can be analyzed quantitatively to
obtain a series of speciﬁc property maps of the sample. The retract curve
can then be used to calculate the slope of the curve (which is called the
modulus) and the minimum of the curve (otherwise known as adhesion
images). The deformation can therefore be calculated and this is the
variation between the zero and maximum force. Following this, the area
between the approach and retract curve can then be used to calculate
energy dissipation.53,55,56 The stiffness of an elastic material can be
measured using Young’s modulus.36,57,58 Young’s modulus is the stress
divided by the corresponding strain, with greater values indicating
increased stiffness or decreased deformability. As each force curve’s data,
can also be stored individually, and quantitative measurements of the
Young’s modulus can be generated by ﬁtting the slope of any force–
distance curve of the image to an appropriate model (in this instance; the
Derjaguin–Muller–Toporov Model.59
Silicon Nitride probes (TAP525−MPP 13120− 10, Bruker, USA) were
employed in all AFM measurements and these probes were speciﬁed to
have a nominal force constant of 200 N.m-1, a resonant frequency
between 430 and 516 kHz (measured by the manufacturer), and a nominal
tip radius of 15 nm. Ten cells per participant were analyzed by selecting a
1μm by 1μm scan area on the periphery of the RBC and performing 128 by
128 data points of individual force curve measurements with a peak force
of 6 μN. As there might be differences in concavity of RBCs, the periphery
of the cells was chosen to ensure that an area that is not affected by the
concavity of the speciﬁc RBC is measured. The scans were performed at 0.6
Hz, which is a tip velocity of 1.2 μm s− 1 and 50 force curves were chosen at
random within the stated area. The ofﬂine software (NanoScope Analysis
version R3, Bruker, USA) was used to process the force curves. A goodness-
of-ﬁt model was used to obtain the coefﬁcient of determination (R2)
between the modulus model and the data given by the acquired curve,
determined by calculating the ratio of explained variation to total variation
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in the data set. We only used force curves with a coefﬁcient of
determination of 0.85 and above for modulus measurements.
Atomic force microscopy
To have statistical power of 95% to detect a statistically signiﬁcant
treatment effect at a 1% signiﬁcance level, a sample of 35 T2D patients is
required, whereas 47 patients are needed for statistical power of 99% (see
Rosner60) for details on sample size calculations in before–after studies). A
sample of 60 T2D patients was recruited and AFM data (RBC membrane
elasticity measurements) were available for 56 of these individuals. The
elasticity measurement distributions were analyzed for each patient.
Owing to the asymmetry of these distributions, it was decided to calculate
for each patient the median elasticity measurement value from the
corresponding nave T2D blood sample. The same was done for each
patient for the T2D blood sample exposed to OPCs. Thus, we obtained 56
matched (paired) median values to be utilized as reference values in the
various graphical and statistical analyses done. These analyses included the
drawing of histograms and box and whisker diagrams, testing for
normality, testing for a difference in the medians between the nave T2D
blood samples and T2D blood samples exposed to OPCs and testing for a
difference in the variation (spread) between these two groups of blood
samples.
Statistical analyses were done using SAS/STAT and SAS/IML software,
Version 9.4 of the SAS System for Windows (SAS Institute, Cary, NC, USA).
The histograms and box and whisker diagrams were drawn with
Wolfram Mathematica, Version 10.4 (Wolfram Research, Champaign,
IL, USA).
Scanning electron microscopy
The SEM experiment was conducted by comparing the naive T2D blood
samples with T2D blood samples exposed to OPCs. Whole blood samples
from the 20 healthy individuals were also collected, scanned and analyzed
as a control group. After the blood was collected, 10 μl of whole blood
with 5 μl thrombin (to create an extensive ﬁbrin network) were placed
directly on a glass cover slip, ﬁxed, dehydrated, dried, mounted and coated
with carbon according to previously described methods.4,61 A Zeiss ULTRA
Plus FEG-SEM with InLens capabilities was used and micrographs were
taken at 1 kV.
RESULTS
The demographic data for the group of 60 patients with T2D is
summarized in Table 1. The information collected included
glucose measured at the time of sample collection, HbA1c values
as well as chronic medication typically administered to T2D
patients. Table 1 shows that, although almost all T2D participants
(97%) are taking hypoglycaemic medication, the samples group
still represents a poorly controlled diabetic population. Besides
medication for glucose control, the T2D group also includes
individuals on medication for dyslipidaemia and hypertension,
whereas some are taking anticoagulants. The control group of 20
healthy individuals was selected to be age and gender matched to
the T2D group.
An important consideration for this study was the possible
interactions of OPCs with the currently used mediations that
typical poorly controlled diabetes patients may be taking (see
Table 1. Summary of patient demographic data and medication
TYPE II diabetes demographic data and medication summary
% Distributions Individuals with
diabetes
Number of female patients (%) 34 (57%)
Number of male patients (%) 26 (43%)
Total no of patients 60
Average age± s.d. 56.7± 9.9
Average HbA1c (%)± s.d. 9.0± 2.2
Average glucose level (mmol l− 1)± s.d. 10.1± 5.1
Number of patients taking anticholesterol
medication (%)
40 (67%)
Number of patients taking hypoglycaemic
medication (%)
58 (97%)
Number of patients taking anticoagulants
medication (%)
31 (52%)
Number of patients taking antihypertensive
medication (%)
44 (73%)
Figure 1. Type II diabetes, symptoms suggestive of systemic inﬂammation, typical medication for the comorbidities and solution for disease
tracking based on an individualized, precision medicine approach.
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Figure 1). Table 2 shows possible interactions of OPCs with
typically prescribed chronic medication.
Descriptive statistics for the naive T2D group and the T2D group
treated with OPCs are summarized in Table 3, whereas Figures 2
and 3 illustrate paired histograms and box and whisker diagrams
for the two diabetes groups. It is clear from these diagrams that
both groups are positively skewed and hence non-normal. The
non-normality was conﬁrmed with various tests for normality,
including the Anderson–Darling62 and Shapiro–Wilk tests63 (see
Table 3). Figure 4 shows a box and whisker diagram for the control
group of 20 healthy individuals.
Owing to the non-normality of the data, non-parametric
hypothesis tests were utilized to compare the elasticity measure-
ment values between the two groups of blood samples. First, with
the Wilcoxon matched pairs test64 no statistically signiﬁcant
difference in the median elasticity measurement values between
the naive T2D blood samples and T2D blood samples exposed to
OPCs was found (P-value = 0.3083). This is also evident from the
box and whisker diagrams in Figure 3. However, these box and
whisker diagrams do suggest that the variation in elasticity
Table 2. Medication typically administered to diabetes type II patients and possible interactions with OPCs
Medication Selected references
Glucose control
Effect on blood glucose levels in general No evidence of interaction
Antihyperglycemic drug dimethylbiguanide (metformin/
glucophage)
No evidence of interaction
Actraphane (mixture of fast-acting insulin and long-acting
insulin)
No evidence of interaction
Actrapid (human soluble insulin) No evidence of interaction
Humulin (70% human insulin isophane suspension and
30% human insulin injection (rDNA origin))
No evidence of interaction
Protophane (intermediate-acting insulin) No evidence of interaction
Hypertension control
Effect on blood pressure in general Had no effect on blood pressure or heart rate.46,55 In patients with mild blood
pressure, blood pressure was normalized and thromboxane levels lowered.47,56
Coversyl (active ingredient is perindopril arginine which is
a angiotensin-converting enzyme inhibitor)
No evidence of interaction
Amlodopine (calcium channel blockers) Reduced the dosage of the calcium channel blocker nifedipine signiﬁcantly; plasma
levels of endothelin-1 were reduced and concentrations of prostacyclin were
elevated47,57
Carvedilol (beta and alpha adrenoceptor blocker with
antioxidant activity)
No evidence of interaction
Adalat (nifedipine) calcium channel blocker) No evidence of interaction
Anti-clotting medication
Aspirin (acetylsalicylic acid) An inhibitory effect on platelet aggregation similar to aspirin.44,47,55,56,58 Does not
affect INR (bleeding tendency) in patients taking aspirin.46
Cholesterol medication
Effect on blood lipid levels in general Decreases LDL-cholesterol, increases HDL-cholesterol levels, no signiﬁcant change in
total cholesterol or triglycerides.46,59 No statistically signiﬁcant improvement in total
cholesterol or LDL levels compared with placebo.44,60
Simvastatin No evidence of interaction
Lipitor No evidence of interaction
Table 3. Descriptive statistics and normality tests for the group of
participants with type II diabetes (naive T2D) and for the same group
of participants treated with OPCs (T2D+OPCs)
Naive T2D T2D group treated
with OPCS
Descriptive statistics
Sample size 56 56
Mean 30197.76 32730.20
s.d. 17693.60 21559.00
Median 26622.00 29326.25
75 percentile 36202.50 46812.00
25 percentile 16952.00 15545.80
Interquartile range 19250.50 31266.20
Maximum 106986.50 103698.00
Minimum 8093.00 4499.00
Range 98893.50 99199.00
P-values for normality tests
Anderson–Darling 0.0001 0.0270
Shapiro–Wilk o0.0001 0.0047
Abbreviations: OPCs; oligomeric proanthocyanidins; T2D, type II diabetes.
Figure 2. Paired histograms comparing the group of participants
with type II diabetes (naive T2D) and the same group of participants
treated with OPCs (T2D+OPCs).
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measurement values for the T2D group treated with OPCs is larger
than the variation in elasticity measurement values for the naive
T2D group. Using the modiﬁcation of Wilcox65 of the Morgan–
Pitman test,66,67 a signiﬁcant difference in variation between the
elasticity measurement values of the two groups of blood samples
was found (P-valueo0.0001).
Scanning electron microscopy
SEM followed the same trends as the AFM results, and it seems as
if the OPC changes the RBC membrane to be comparable to that
of a typical healthy RBC membrane (see Figure 5). A healthy RBC
membrane shows a smooth undulating structure, where RBCs
from T2D are known to be eryptotic, with a membrane that is
much rougher.4,61
Eryptosis is programmed RBC cell death, similar to that of
apoptosis, and is found in (all) inﬂammatory conditions. For
comprehensive reviews on this process, see Pretorius et al.38
With the addition of the OPC, the eryptotic RBC structure is
reversed, and the membrane roughness are slightly improved,
compared with that of a typical healthy RBC.
DISCUSSION
In a healthy RBC, the neutral phosphatidylcholine and sphingo-
myelin are mostly found on the outside, and the charged
phosphatidylserine, phosphatidylinositol and phosphatidyletha-
nolamine, are found mostly on the inner membrane leaﬂet.36,41 In
most inﬂammatory conditions, RBCs have been noted to show
eryptosis (similar to apoptosis, but called eryptosis owing to
theabsence of mitochondria and nuclei); for extensive reviews on
eryptosis see various publications.38,68–73 During eryptosis, a
membrane phosphatidylserine-ﬂip occurs, and phosphatidylserine
is then present on the outside leaﬂet of the RBC membranes.74–79
Ultimately, eryptosis results in an inﬂammatory RBC presence in
the circulation. Eryptotic RBCs are known to themselves produce
membrane microparticles and these microparticles in itself are
inﬂammatory.80 In all inﬂammatory conditions, RBCs demonstrate
enhanced eryptosis and a pathological membrane structure with a
changed elasticity. This was previously also demonstrated in
T2D.61,81 The pathological nature T2D RBCs, together with the
general hypercoagulability seen in the condition,82 fundamentally
inﬂuences the inﬂammatory proﬁles of the patients. Eryptosis is
Figure 3. Box and whisker diagrams for the group of participants
with type II diabetes (naive T2D) and the same group of participants
treated with OPCs (T2D+OPCs).
Figure 4. Box and whisker diagram for the control group of 20
healthy individuals.
Figure 5. (a) A typical RBC membrane from a healthy individual.
(b) A typical RBC membrane from a type II diabetes individual. (c)
A typical RBC membrane from a type II diabetes individual, treated
with an OPC.
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also seen in conditions like anemia.83 Previously, it was also shown
that pathological RBC structure, with an accompanying changed
viscoelasticity and hypercoagulability of whole blood and plasma,
are found in conditions like Alzheimer’s and Parkinson’s
disease,84–86 hyperferritinemia and haemochromatosis.87
Procyanidins and proanthocyanidins have been shown to have
antioxidative and anti-inﬂammatory properties.88,89 Preliminary
clinical trials have been conducted in a number of indications and
clinical contexts, including asthma, CVD and diabetes.42–47,51,90,91
It has been shown that OPCs increase RBC membrane ﬂuidity
in vitro, potentially owing to inducing modiﬁcation of the lipid
bilayer and lipid–protein interactions as shown by Sivonová et al.42
Sivonová et al. studied the in vitro effect of polyphenol rich plant
extract, trademarked as Pycnogenol, on RBC membrane ﬂuidity.
They found that the extract signiﬁcantly increased the membrane
ﬂuidity especially at the membrane surface as compared with
untreated RBCs. They also found that the extract had protective
effect against lipid peroxidation, generation of thiobarbituric acid
reactive products and oxidative hemolysis induced by H2O2. They
stated that, even though the exact mechanisms are unknown, it is
thought that pycnogenol can reduce the lipid peroxidation and
oxidative hemolysis either by reducing free radicals or by
chelating metal ions, or by both. They concluded that the extract
possibly modiﬁes membrane-dependent processes not only by its
chemical action, but also by interacting directly with cell
membranes and/or penetrating the membrane and therefore
inducing modiﬁcation of the lipid bilayer and lipid–protein
interactions.42
In the current study, the protective antioxidant effect of OPCs
on the local mechanical properties of the erythrocyte membrane
was evaluated, and therefore the membrane elasticity of
erythrocytes of patients with T2D, using AFM techniques.
The Wilcoxon matched pairs test64 showed no statistically
signiﬁcant difference in the median elasticity measurement values
between the T2D sample group and the same group exposed to
OPCs (P-value = 0.3083). From this data it can be interpreted that
the OPCs had no effect, or at least not a measurable effect, on the
local mechanical properties of the erythrocyte membrane by
means of AFM, and therefore the membrane elasticity of
erythrocytes.
Using the modiﬁcation of Wilcox65 of the Morgan–Pitman
test,66,67 a signiﬁcant difference in variation between the elasticity
measurement values of the two groups was found (P-value
o0.0001). Oxidative stress has been associated with premature
erythrocyte aging.92 It can therefore be assumed that in T2D more
erythrocytes would be expected to measure as aged, lesser
deformable erythrocytes92 as seen in this study and to have
smaller Young’s modulus values and a smaller variance in
membrane elasticity as seen by the AFM data (refer to Figure 3).
The results showed that at least some of the samples were
positively affected in the treated T2D group. It can therefore be
presumed that the protective antioxidant effect of OPCs on the
local mechanical properties of the erythrocyte membrane, and
therefore the membrane elasticity of patients with T2D as
measured by AFM, has an improving effect in comparison with
the untreated T2D group.
These results are comparable to the ﬁndings of Pretorius (2015)
where the authors investigated the effect of iron chelators
deferoxamine or deferasirox on T2D erythrocytes by means of
SEM and AFM. They found that treatment with either deferasirox
or deferoxamine improved the Young’s modulus values towards
normal values. This indicates a possible improvement in the
elasticity of the cells.4 However, when they compared the elasticity
measurements individually after treatment, a more complex
picture emerges owing to the substantial variation in the two
groups.4 Similar variation was found in this study. In this study we
found that a detailed analysis showed that the effect of the iron
chelators on membrane elasticity was patient-speciﬁc.4
This is further supported after closer inspection, at × 150 000
magniﬁcation (refer to Figure 5), the erythrocyte membranes are
visible. The T2D membrane ultrastructure appears much more
rough and textured than that of healthy erythrocytes, possibly due
to membrane phospholipid scrambling, associated with oxidative
stress.86 The OPCs-treated sample shows a visibly smoother
surface of the erythrocyte membranes, as compared with the
untreated T2D erythrocytes.
It is also important to note that AFM is generally considered to
be an informative technique that is frequently used in erythrocyte
structural studies using Young’s modulus to measure membrane
stiffness and elasticity.36,57,58 However, in this study relatively
complex statistical methodology was needed to statistically
compare treated and untreated T2D groups. The technique was
also found to be a timeous technique when a larger samples
group is being studied. In addition, it is considered to be a
complicated method to implement as a patient-orientated
approach.36
CONCLUSION
In conclusion, the protective antioxidant properties of OPCs
improved membrane elasticity as shown by a signiﬁcant
difference (P-valueo0.0001) in variation between the elasticity
measurement values of the two groups T2D treated and
untreated) when using the modiﬁcation of Wilcox65 of the
Morgan–Pitman test.66,67 Using SEM analysis these ﬁndings are
further supported by the visibly smoother membrane surface
viewed at × 150 000 magniﬁcation. The data from AFM showed
that this is possibly due to an improvement towards a more
normal variance of elasticity, and possibly contributing to the
improvement of biophysical shape changes as seen in SEM
analyses.
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